Disintegration/dissolution profiles of copies of Fosamax (alendronate)

Current Medical Research and Opinion

Volumn 19, Issue 8, 2003, Pages 781-789

  Epstein, Solomon ^a,b   Cryer, B ^c   Ragi, S ^d   Zanchetta, J R ^e,f   Walliser, J ^g   Chow, J ^h   Johnson, M A ^h   Leyes, A E ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^e Instituto de Investigaciones Metabolicas   (Argentina)

^f UNIVERSIDAD DEL SALVADOR   (Argentina)

^g HOSPITAL ÁNGELES DEL PEDREGAL   (Mexico)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Disintegration; Dissolution; Efficacy; Safety

Indexed keywords

ALENDRONIC ACID; ARENDAL; DEFIXAL; ENDRONAX; FIXOPAN; FOSMIN; FOSVAL; GENALMEN; NEOBON; OSTENAN; OSTEOMAX; OSTEOMIX; OSTEOPLUS; REGENESIS; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; DRUG CAPSULE; DRUG MANUFACTURE; DRUG SCREENING; DRUG SOLUBILITY; PILOT STUDY; STANDARD; TABLET DISINTEGRATION; UNITED STATES;

ALENDRONATE; BIOLOGICAL AVAILABILITY; DRUGS, GENERIC; ESOPHAGITIS; HUMANS; LATIN AMERICA; OSTEOPOROSIS, POSTMENOPAUSAL; PILOT PROJECTS; SAFETY; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY; WATER;

EID: 0345276663     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002577     Document Type: Article

References (30)

1. Videau J-Y. Making medicines safe. Bull World Health Org 2001;79:87
2. Rägo L. Ensuring access to drug products that are of acceptable quality. WHO Pilot Procurement Quality and Sourcing ('prequalification') project. World Health Organization Web site. Available at: http://www.who.int/medicines/organization/par/briefing/9prequalification.ppt Accessed September 4, 2003
3. Schnitzer TJ. Update on alendronate for osteoporosis: once-weekly dosing. Expert Opin Pharmacother 2001;2:1461-72
4. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
5. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50
6. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, et al. Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15
7. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
8. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 1997;277:1159-64
9. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Rev 2002;23:508-16
10. Cummings SR, Black DM, Thompson DE, Applegate WB, Barret-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
11. Fosamax Prescribing Information. Physicians' Desk Reference, 55th edn. Montvale, NJ: Medical Economics Co; 2001:1930-6
12. Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-43
13. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract 1999;101 (Suppl):51-61
14. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21
15. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study, Mayo Clin Proc 2002;77:1044-52
16. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, et al., for the Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96
17. United States Pharmacopeia, Chapter 701 24th edn. 2000:1941
18. De Marco JD, Biffar SE, Reed D, Brooks M. J Pharm Biomed Anal 1989;7:1719-27
19. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98
20. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315-28
21. Castell DO. Editorial. 'Pill esophagitis' - the case of alendronate. N Engl J Med 1996;335:1058-9
22. Ovartlarnporn B, Kulwichit W, Hiranniramol S. Medication-induced esophageal injury: report of 17 cases with endoscopic documentation. Am J Gastroenterol 1991;86:748-50
23. Drake WM, Worsley DF, Lentle BC, Kendler DL, Monitoring esophageal transit of wax-polished alendronate in healthy postmenopausal women: a new technique for the study of pill transit time. Curr Ther Res Clin Exp 2002;63:103-9
24. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032-7
25. Channer KS, Virjee JP. The effect of size and shape of tablets on their esophageal transit. J Clin Pharmacol 1986;26:141-6
26. Bailey RT Jr, Bonavina L, McChesney L, Spires KJ, Muilenberg MI, McGill JE, et al. Factors influencing the transit of a gelatin capsule in the esophagus. Drug Intell Clin Pharm 1987;21:282-5
27. Channer KS, Virjee JP. The effect of formulation on oesophageal transit. J Pharm Pharmacol 1985;37:126-9
28. Perkins AC, Wilson CG, Blackshaw PE, Vincent RM, Dansereau RJ, Juhlin KD, et al. Impaired oesophageal transit of capsule versus tablet formulations in the elderly. Gut 1994;35:1363-7
29. Marvola M, Vahervuo K, Sothmann A, Marttila E, Rajaniemi M. Development of a method for study of the tendency of drug products to adhere to the esophagus. J Pharm Sci 1982; 71:975-7
30. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2